MedPath

Bremelanotide

Generic Name
Bremelanotide
Brand Names
Vyleesi
Drug Type
Biotech
Chemical Formula
-
CAS Number
189691-06-3
Unique Ingredient Identifier
6Y24O4F92S
Background

Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women. Bremelanotide does not interact with alcohol. The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.

Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. Other drugs used to treat female sexual dysfunction include flibanserin, estrogen, ospemifene, and prasterone.

Bremelanotide was granted FDA approval on 21 June 2019.

Indication

Bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug.

Associated Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Associated Therapies
-
finance.yahoo.com
·

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. (RYTM), highlighting its focus on rare obesity disorders with Imcivree, showing a 14% revenue increase to $33.3M in Q3 2024. With a $76 price target, optimism is high for its MC4 biology expertise and Phase 3 trial results for hypothalamic obesity expected in 2025.
finance.yahoo.com
·

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin's MC4R long-acting peptide and oral small molecule compounds aim to address unmet needs in obesity treatment, with topline data from Phase 2 BMT-801 study expected in Q1 2025. The company plans to advance obesity programs and start multiple clinical trials in 2025 for general obesity, weight loss management, and rare MC4R pathway diseases.
investing.com
·

Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024

Palatin Technologies reported Q4 and FY 2024 financials, including a $171 million Vyleesi sale to Cosette Pharmaceuticals, no Q4 product sales, reduced operating expenses, and successful Phase III trials for PL9643 for dry eye disease. The company plans to complete Phase III trials for dry eye disease by end of 2025 and file an NDA in H1 2026, while seeking collaborations for key programs in obesity and dry eye disease.
biospace.com
·

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides ...

Palatin Technologies announces financial results for fiscal Q4 and FY 2024, highlighting key clinical milestones for obesity, dry eye disease, male sexual dysfunction, ulcerative colitis, and diabetic nephropathy programs. Patient dosing for obesity treatment with MC4R agonist plus GLP-1 is set to commence in Q3 2024, with topline results expected in Q1 2025. PL9643 for dry eye disease is expected to start patient enrollment in Q1 2025, with potential NDA submission in H1 2026. Bremelanotide co-formulated with a PDE5i for erectile dysfunction is anticipated to begin pharmacokinetics study in Q1 2025. Interim analysis for ulcerative colitis treatment is expected in Q4 2024, with topline results in Q1 2025. Topline results for diabetic nephropathy treatment are expected in Q4 2024. The company also reports a net loss of $8.6 million for Q4 2024 and $29.7 million for FY 2024.
investing.com
·

Palatin advances on multiple clinical programs, eyes key milestones

Palatin Technologies advances clinical programs in dry eye disease, obesity, male sexual dysfunction, and ulcerative colitis. Key milestones include FDA agreements on trial protocols, patient enrollment for dry eye disease studies in Q4 2024, and Phase 2 obesity study results in H1 2025. The company also sold Vyleesi to Cosette Pharmaceuticals for up to $171 million, retaining rights for obesity and erectile dysfunction. Palatin faces financial challenges with a net loss of $8.4 million in Q3 2024, but secured $6.1 million from warrant exercises.
© Copyright 2025. All Rights Reserved by MedPath